Moderna forecasts $8-15 billion in sales from its respiratory vaccines by 2027
Moderna announced on Tuesday that it expects to generate between $8 billion and $15 billion in sales from its respiratory vaccines, including Covid, RSV, flu, and other respiratory illnesses, by 2027. The biotech firm also stated that it expects to…